Navigating the legal landscape of medical marijuana dispensing

The therapeutic use of cannabinoids has shifted from a fringe conversation to a mainstream clinical consideration in pharmacies from Perth to Brisbane. Pharmacists in community and hospital settings are fielding questions about medicinal cannabis with increasing frequency, often from patients who have read anecdotal reports online or heard stories from friends across cities like Melbourne and regional New South Wales. The shift creates a duty to dispense accurately, counsel clearly, and remain compliant with a layered regulatory framework.

Australia's approach differs from jurisdictions where recreational cannabis has been legalised. The Therapeutic Goods Administration (TGA) oversees access through tightly defined schemes, and Schedule 8 and Schedule 4 of the Poisons Standard govern how products are handled. For pharmacists, every script for medicinal cannabis must be treated with the same rigour as any other controlled or high-risk medication, with additional paperwork layered on top.

Understanding the legal landscape is also a professional responsibility. Pharmacists registered with AHPRA are expected to maintain competence in evolving therapeutic areas. Whether the script arrives from a neurologist in Sydney, a pain specialist in Adelaide, or a GP in regional Queensland, the dispensing pharmacist is the final checkpoint before the patient receives the product.

This article walks through the regulatory architecture, the clinical pathways that bring patients to the pharmacy counter, and the practical considerations that determine whether dispensing goes smoothly. It also covers stock availability, prescriber authorisation, and patient counselling in the Australian context.

The regulatory framework governing medicinal cannabis

The TGA classifies medicinal cannabis products as either registered medicines or unregistered goods accessed through special pathways. As of mid-2025, only a handful of products hold full ARTG registration, including nabiximols (Sativex) for multiple sclerosis spasticity and cannabidiol (Epidyolex) for paediatric epilepsies. Most scripts rely on the Special Access Scheme (SAS) or the Authorised Prescriber pathway.

Under SAS Category B, a prescriber applies to the TGA on a patient-by-patient basis with clinical justification for an unregistered product. Approvals usually arrive within a few working days, and urgent cases can be fast-tracked. Pharmacists receive the approval alongside the prescription and retain documentation as part of the patient's clinical record, mirroring storage expectations for other high-schedule medicines.

The Authorised Prescriber scheme offers a different rhythm. Specialists or GPs with appropriate endorsement can apply to prescribe a specific cannabinoid product for a class of patients without seeking case-by-case TGA approval. This streamlines repeat prescribing for common indications. Pharmacists still verify that the prescriber holds active Authorised Prescriber status, often by contacting the TGA or checking the published list of approved practitioners.

Products are typically scheduled under Schedule 8 when they contain tetrahydrocannabinol, or Schedule 4 for CBD-dominant preparations with negligible THC. This split affects storage, register-keeping, and destruction protocols when expired stock is returned. State and territory drugs and poisons regulations add another layer on top of the Commonwealth framework.

Pathways for patient access in Australia

Patients rarely arrive with a ready-to-dispense script. Most begin with a GP consultation, although specialist input is common for conditions outside the prescriber's scope. GPs in Hobart and Darwin increasingly complete medicinal cannabis prescribing courses through the Royal Australian College of General Practitioners or accredited providers, expanding the prescriber pool outside metropolitan areas.

Cost remains a significant barrier. Medicinal cannabis products are not subsidised under the Pharmaceutical Benefits Scheme in most cases, so patients pay out of pocket. Monthly supply can range from under one hundred dollars for a low-dose CBD oil to several hundred for higher-THC formulations. Pharmacists in suburban Sydney and Brisbane report patients asking about cheaper alternatives, including over-the-counter low-dose CBD products available at pharmacies since 2024.

Clinical indications driving prescriptions include chronic non-cancer pain, palliative care symptom management, and chemotherapy-induced nausea. The evidence base varies in maturity, and pharmacists are well placed to flag situations where the prescribed product lacks robust trial data for the indication. Conversations about realistic expectations, onset of effect, and adverse events such as sedation and dry mouth should happen at the counter rather than after the patient has left.

Stock availability complicates every other step. Australian pharmacies source medicinal cannabis from a small group of licensed cultivators and importers, and shortages occur periodically. Pharmacists often maintain relationships with two or three suppliers to avoid leaving patients without a repeat supply. When a specific formulation is unavailable, contacting the prescriber to discuss a therapeutic alternative becomes part of the dispensing workflow.

State and territory variations that shape daily practice

Although the TGA sets the national framework, each state and territory applies its own drugs and poisons legislation. In Queensland, all Schedule 8 cannabis products must be reported to the Medicines Monitoring Program. Pharmacists in Brisbane and Townsville handle this through the state's real-time prescription monitoring system, an administrative step absent in every other jurisdiction.

Victoria operates a similarly structured approach but with its own permit requirements for certain prescribers, particularly those initiating treatment for patients without a documented specialist relationship. Pharmacists in Melbourne report that confirming prescriber authority is the single most common reason for delaying a dispense. NSW and the ACT tend to align more closely with TGA approvals without extra state-level permits, which can streamline workflows for pharmacists handling telehealth scripts.

Western Australia has historically been more conservative, with additional safeguards around telepsychiatry prescribing and stricter repeat dispensing monitoring. Pharmacists in Perth often receive calls from interstate prescribers checking whether a script written under SAS elsewhere will be honoured at the WA counter. The answer depends on the approval, the product's schedule, and whether the prescriber's authorisation remains current.

South Australia and Tasmania round out the patchwork with their own nuances around storage and record retention. Pharmacists working in chains that operate across multiple jurisdictions often include a state-by-state table in their compliance manuals. Reviewing that table whenever the TGA updates its guidance is one of the quieter but essential tasks of medicinal cannabis dispensing.

Clinical considerations and product selection

Pharmacists are not prescribers, yet they carry substantial responsibility for verifying that a product matches the clinical intent expressed on the script. Medicinal cannabis comes in oils, capsules, dried flower for vaporisation, and oral sprays, each with different pharmacokinetics. Oils and capsules offer slower onset and longer duration, suitable for chronic symptoms, while vaporised flower provides rapid relief for breakthrough nausea or neuropathic pain spikes.

Ratio matters as much as formulation. CBD-dominant products are favoured for anxiety, sleep disturbance, and inflammatory conditions where psychoactivity is undesirable. THC-containing products carry stronger evidence for spasticity, chronic pain, and appetite stimulation, but introduce concerns around impairment, driving, and workplace safety. Pharmacists in regional Victoria routinely counsel patients about the legal implications of driving with detectable THC, even when used medically.

Drug interactions deserve particular attention. Cannabinoids are metabolised through cytochrome P450 enzymes, especially CYP3A4 and CYP2C19, and can affect plasma concentrations of warfarin, clobazam, certain antidepressants, and some antiepileptics. Pharmacists reviewing a medication profile using polypharmacy management strategies often uncover interactions the prescriber missed, particularly in older patients with multiple comorbidities.

Adverse effects shape counselling. Dry mouth, dizziness, gastrointestinal upset, and fatigue are common in the first weeks. Pharmacists should advise patients to titrate slowly, keep a symptom diary, and schedule a follow-up review after two to four weeks. Pregnant or breastfeeding patients are generally advised against medicinal cannabis unless absolutely necessary, and paediatric patients on CBD for epilepsy require additional liver function monitoring.

Dispensing logistics, storage, and patient counselling

Once a script reaches the dispensary, the operational checklist looks familiar: verify the prescription, confirm prescriber authority, check the patient's identity, and counsel on use. The differences emerge in the details. Documentation must include the TGA approval reference, the product name and batch number, the indication, and a clear record of counselling. Australian pharmacies store these details within their standard dispense software but flag cannabis scripts for separate audit review.

Storage requirements depend on the schedule. Schedule 8 products must be kept in a secure safe meeting state-specific standards, with access restricted to authorised staff. CBD-only Schedule 4 products can sit on the regular dispensary shelf but still require prescription-only handling. Pharmacies stocking vaporisation devices must decide whether accessories are sold alongside the product or referred to a specialist supplier, given sensitivities around drug paraphernalia in some jurisdictions.

Patient counselling is where pharmacists add the most value. Guidance on dose timing, food effects, and what to expect in the first week can determine whether a patient continues therapy or discontinues prematurely. Linking the script to a broader medication review helps integrate medicinal cannabis into the overall treatment plan, and written summaries are appreciated when starting a product with the earthy taste of full-spectrum oils.

Operational steps that support confident dispensing:

• Designating one or two pharmacists as the team's medicinal cannabis champions, responsible for staying current on TGA updates.
• Building a state-by-state compliance reference sheet that flags differences in permits, reporting, and storage.
• Establishing direct communication channels with at least two licensed suppliers to manage stock continuity.
• Creating a standardised counselling checklist that covers dose titration, adverse effects, driving safety, and follow-up planning.

Indications frequently appearing on Australian scripts:

• Chronic non-cancer pain unresponsive to first-line analgesics.
• Spasticity associated with multiple sclerosis or spinal cord injury.
• Refractory epilepsy, particularly paediatric Dravet and Lennox-Gastaut syndromes.
• Chemotherapy-induced nausea and vomiting where standard antiemetics have failed.

Dispensing medical marijuana sits at the intersection of clinical care, regulatory compliance, and patient advocacy. Pharmacists who understand the TGA's access pathways, the state-by-state variations, and the practical realities of stock and counselling position themselves as trusted advisors in a therapeutic area that will only continue to grow. Share this guide with colleagues who are new to medicinal cannabis dispensing, revisit it whenever the regulatory landscape shifts, and keep building the relationships with prescribers and suppliers that make confident dispensing possible.